United States-based Johnson & Johnson has started final stage testing of its COVID-19 vaccine candidate, it was reported on Monday.
The company is testing the vaccine with 60,000 volunteers from around the globe including subjects from the US, South Africa, Brazil, Argentina, Columbia, and Chile.
The firm aims to produce a billion doses of the vaccine on a not for profit basis if proven effective. The vaccine requires one dose and also does not need freezing and can remain viable in its liquid form for several months.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses